Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inupadenant + chemotherapy
- Development stage
- Unknown
- Lead developer
- iTeos Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral (inupadenant), Intravenous (chemotherapy Agents)
01
Overview
A combination therapy consisting of **inupadenant** (a potent, selective, non-brain-penetrant small molecule antagonist of the adenosine A2A receptor) and **standard cytotoxic chemotherapy** (including agents such as carboplatin and pemetrexed, or carboplatin and paclitaxel). This regimen is under investigation for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC) after progression on immunotherapy. Inupadenant works by blocking adenosine-mediated immunosuppression in the tumor microenvironment, thereby enhancing antitumor immune responses. The chemotherapy agents act through direct cytotoxic mechanisms. The combination aims to increase therapeutic efficacy by targeting tumor cell survival both through immune-mediated and direct cytotoxic pathways. The approach is experimental and not approved for any indication.
- Other names
- inupadenant + chemotherapyinupadenant plus chemotherapyinupadenant with chemotherapyinupadenant + carboplatin + pemetrexedinupadenant + paclitaxel + carboplatin
02
Targets
ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on inupadenant + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inupadenant + chemotherapy.